This is a placebo controlled study comparing Rimonabant 5 mg per day for 90 days with placebo for the same period. Objective is to improve walking abilities of spinal cord injury individuals (incomplete lesions) and demonstrate that it is a safe treatment in spinal cord injury population.

Start Date01 Nov 2022

Sponsor / Collaborator

Hospital Nacional de Parapléjicos de Toledo

NCT05398913 / CompletedPhase 1/2IIT

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury: a Proof-of-concept Study

Randomized placebo-controlled safety and feasibility study with crossover design (3 arms). Placebo or Rimonabant 2.5mg or Rimonabant 5mg will be administered for 5 days. Exploratory efficacy will be tested using six-min walking test.

Start Date12 May 2021

Sponsor / Collaborator

Hospital Nacional de Parapléjicos de Toledo

EUCTR2011-003104-20-BE / Not yet recruitingPhase 4

The effect of Acomplia® (rimonabant) on esophageal sensitivity and gastric accommodation during food intake in healthy volunteers: a single-blind, placebo-controlled study - Effec Acomplia gastric sensitivity

Start Date06 Oct 2011

Sponsor / Collaborator-

100 Clinical Results associated with Rimonabant

100 Translational Medicine associated with Rimonabant

100 Patents (Medical) associated with Rimonabant

2,071

Literatures (Medical) associated with Rimonabant

01 Apr 2024·Journal of ethnopharmacology

Ayahuasca and its major component harmine promote antinociceptive effects in mouse models of acute and chronic pain

Article

Author: Nunes, Victor Luiz Correia ; Colavolpe, Paulo Oliveira ; Santana, Rejane Conceição ; Gomes, Juliana de Medeiros ; Villarreal, Cristiane Flora ; Lauria, Pedro Santana Sales ; Couto, Ricardo David ; Silva, Marcelo Sobral da ; Soares, Milena Botelho Pereira ; Abreu, Lucas Silva

ETHNOPHARMACOLOGICAL RELEVANCE:

Ayahuasca (AYA) is a psychedelic brew used in religious ceremonies. It is broadly used as a sacred medicine for treating several ailments, including pain of various origins.

AIM OF THE STUDY:

To investigate the antinociceptive effects of AYA and its mechanisms in preclinical models of acute and chronic pain in mice, in particular during experimental neuropathy.

MATERIALS AND METHODS:

The antinociceptive effects of AYA administered orally were assessed in the following models of pain: formalin test, Complete Freund's Adjuvant (CFA)-induced inflammation, tail flick test, and partial sciatic nerve ligation model of neuropathic pain. Antagonism assays and Fos immunohistochemistry in the brain were performed. AYA-induced toxicity was investigated. AYA was chemically characterized. The antinociceptive effect of harmine, the major component present in AYA, was investigated.

RESULTS:

AYA (24-3000 μL/kg) dose-dependently reduced formalin-induced pain-like behaviors and CFA-induced mechanical allodynia but did not affect CFA-induced paw edema or tail flick latency. During experimental neuropathy, single treatments with AYA (24-3000 μL/kg) reduced mechanical allodynia; daily treatments once or twice a day for 14 days promoted consistent and sustained antinociception. The antinociceptive effect of AYA (600 μL/kg) was reverted by bicuculline (1 mg/kg) and methysergide (5 mg/kg), but not by naloxone (5 mg/kg), phaclofen (2 mg/kg), and rimonabant (10 mg/kg), suggesting the roles of GABA_A and serotonergic receptors. AYA increased Fos expression in the ventrolateral periaqueductal gray and nucleus raphe magnus after 1 h, but not after 6 h or 14 days of daily treatments. AYA (600 μL/kg) twice a day for 14 days did not alter mice's motor function, spontaneous locomotion, body weight, food and water intake, hematological, biochemical, and histopathological parameters. Harmine (3.5 mg/kg) promoted consistent antinociception during experimental neuropathy.

CONCLUSIONS:

AYA promotes consistent antinociceptive effects in different mouse models of pain without inducing detectable toxic effects. Harmine is at least partially accountable for the antinociceptive properties of AYA.

01 Mar 2024·Pharmacology, biochemistry, and behavior

Somatic and anxiety-like behaviors in male and female rats during withdrawal from the non-selective cannabinoid agonist WIN 55,212–2

Article

Author: Sternitzky, Anna R ; Spencer, Sade M ; Brewer, Abigail L ; Felter, Claire E

Synthetic cannabinoids are associated with higher risk of dependence and more intense withdrawal symptoms than plant-derived Δ9-tetrahydrocannabinol (THC). Avoidance of withdrawal symptoms, including anxiogenic effects, can contribute to continued cannabinoid use. Adult male and female Long-Evans rats were given escalating doses of WIN 55,212-2 (WIN) via twice daily intrajugular infusions. Precipitated withdrawal was elicited with SR 141716 (rimonabant) 4 h after the final infusion. Global withdrawal scores (GWS) were compiled by summing z-scores of observed somatic behaviors over a 30-min period with locomotor activity simultaneously collected via beam breaks. Rimonabant precipitated withdrawal in female and male rats at 3 or 10 mg/kg, respectively, but the individual behaviors contributing to GWS were not identical. 3 mg/kg rimonabant did not impact locomotor behavior in females, but 10 mg/kg decreased locomotion in male controls. Spontaneous withdrawal observed between 6 and 96 h after the final infusion was quantifiable up to 24 h following WIN administration. Individual behaviors contributing to GWS varied by sex and time point. Males undergoing spontaneous withdrawal engaged in more locomotion than females undergoing withdrawal. Separate groups of rats were subjected to a battery of anxiety-like behavioral tests (elevated plus maze, open field test, and marble burying test) one or two weeks after WIN or vehicle infusions. At one week abstinence, sex-related effects were noted in marble burying and the open field test but were unrelated to drug treatment. At two weeks abstinence, females undergoing withdrawal spent more time grooming during marble burying and performed more marble manipulations than their male counterparts. WIN infusions did not impact estrous cycling, and GWS scores were not correlated with estrous at withdrawal. Collectively, these results show qualitative sex differences in behaviors contributing to the behavioral experience of cannabinoid withdrawal supporting clinical findings from THC.

01 Mar 2024·Pharmacology, biochemistry, and behavior

Differential disruption of response alternation by precipitated Δ9-THC withdrawal and subsequent Δ9-THC abstinence in mice

Article

Author: Eckard, Matthew L ; Kinsey, Steven G

In addition to overt somatic symptoms, cannabinoid withdrawal can also manifest as disruptions in motivation and attention. Experimental animal models using operant-conditioning approaches reveal these differences, in either antagonist-precipitated or spontaneous withdrawal models. However, these processes have yet to be characterized in the same subjects simultaneously. To differentiate between motivational and attentional processes disrupted in cannabinoid withdrawal, the current study used a response alternation task in which a fixed-ratio (FR) schedule repeatedly alternated between two spatially distinct response options throughout daily training sessions. This task yielded traditional measures of motivation (e.g., response latency) as well as attention (e.g., responses to the incorrect side). After two weeks of training, male and female C57BL/6 J mice either received vehicle or Δ⁹-THC (10 mg/kg, s.c.) twice daily for 5 days. On the 6th day, all mice received their final injection of vehicle or Δ⁹-THC followed 30 min later by injection of the CB₁ receptor selective inverse agonist rimonabant (2 mg/kg, i.p.) to precipitate withdrawal. Testing continued for 3 days post-rimonabant to assess how THC abstinence impacted task performance. Whereas rimonabant decreased response rates to equal degrees in THC-treated and vehicle-treated mice, THC-treated mice showed longer session times, longer response latencies, and more errors per reinforcer. Only THC-treated mice showed a longer latency to switch after committing an error reflecting that precipitated withdrawal impacted measures of both motivation and attention. During the 3-day abstinence window, performance of vehicle-treated mice returned to baseline, but THC-treated mice continued to show disruptions in motivational measures. Importantly, attentional measures (errors and latency to switch after an error) were unaffected by THC abstinence. These data suggest that precipitated and "spontaneous" cannabinoid withdrawal may be qualitatively and quantitatively distinct withdrawal conditions with precipitated withdrawal disrupting both attentional and motivational processes, while abstinence may only affect motivation.

News (Medical) associated with Rimonabant

10 Jun 2024

·www.fiercebiotech.com

Skye Bioscience ends eye disease R&D efforts after glaucoma drug's phase 2 fail

Skye will not only halt all work on SBI-100 but end its ophthalmology R&D ambitions entirely. Skye Bioscience’s share price tumbled in pre-market trading Monday, as the biotech announced a strategic refocus in the wake of a phase 2 trial failure. The company’s stock dropped by 28% to $7.90 as of 8:15 a.m. ET on Monday, compared to a Friday closing price of $10.94 after the biotech disclosed that its lead asset, a cannabinoid receptor-1 (CB1) agonist called SBI-100, failed to demonstrate a statistically significant lowering of intraocular pressure in a mid-stage trial across 56 patients with primary open-angle glaucoma or ocular hypertension. As recently as April, Skye had been attributing its work getting SBI-100 into the phase 2 trial—which completed dosing in February—as one of the reasons for being able to bounce its shares from the over-the-counter securities market to the Nasdaq Global Market. But in response to today’s clinical fail, Skye will not only halt all work on SBI-100 but end its ophthalmology R&D ambitions entirely. From now on, all resources are being funneled into the company’s metabolic program, which is headed up by CB1 inhibitor nimacimab. A phase 2 trial of nimacimab in obesity is due to begin dosing in the third quarter and Skye said the strategic pivot would extend its operating runway into 2027. The company had already “laid the groundwork for our metabolic program” over the last year, according to CEO Punit Dhillon, with the aim of “diversifying our product portfolio’s disease targets and therapeutic mechanisms.” “With this data outcome from our glaucoma program, we will now focus 100% of our efforts on broadening our metabolic clinical pipeline,” Dhillon added in the June 10 release. “We believe that nimacimab’s unique mechanism of peripheral CB1 inhibition positions it to potentially contribute to the need for higher-quality, sustainable weight loss and better treatments for co-morbid conditions amidst an incretin-biased anti-obesity therapeutic landscape.” “We will look forward to sharing updates on this clinical program and advancing nimacimab through to data in 2025,” the CEO added. Inhibiting CB1 has shown potential to address a “broad range of diseases with notable unmet medical needs” including obesity, chronic kidney disease and metabolic dysfunction-associated steatohepatitis (MASH), the biotech noted in the release. However, the modality doesn’t have a great track record. In fact, CB1 agonists have been tied to one of the biggest pharma flops of recent decades, when Sanofi and Aventis’ obesity drug Acomplia was pulled from European markets in 2008 over risks of depression and suicidal thoughts.

Phase 2

11 Jan 2024

·medcitynews.com

FDA’s Preliminary Review of GLP-1 Meds Finds No Tie to Suicidal Thoughts, Actions

An FDA inquiry has found no evidence so far that GLP-1 drugs for diabetes and weight loss cause suicidal thoughts or actions. The review was prompted by reports in the FDA Adverse Event Reporting System, or FAERS, a database that collects information about adverse events that may be linked to a medication. A report in FAERS does not establish causation, nor has information in the reports been verified. The FDA said on Thursday that over the last several months, it has reviewed reports of suicidal thoughts or actions in FAERS as well as data from clinical trials. The information in these reports was limited and can be influenced by other factors, the FDA said. Consequently, the agency said it determined the reports did not demonstrate a clear relationship with GLP-1 drugs. This finding is preliminary. “However, because of the small number of suicidal thoughts or actions observed in both people using [GLP-1 receptor agonists] and in the comparative control groups, we cannot definitively rule out that a small risk may exist; therefore, FDA is continuing to look into this issue,” the agency said in the drug safety communication. The class of GLP-1 drugs are engineered versions of peptides that bind to the GLP receptor and activate it, stimulating the secretion of the blood sugar-regulating hormone insulin. Drugs in this class were initially approved as treatments for type 2 diabetes. But these medications also suppress appetite, leading to weight loss. Novo Nordisk’s Wegovy and newly approved Eli Lilly drug Mounjaro are GLP-1 agonists that have won FDA approvals for weight management. The most common side effects reported for GLP-1 drugs are gastrointestinal problems, such as diarrhea, nausea, stomach discomfort, and constipation. Europe was first to explore the potential association of GLP-1 drugs and suicide. Last July, the European Medicines Agency announced that its Pharmacovigilance Risk Assessment Committee (PRAC) was reviewing the risk of suicidal thoughts following reports by Icelandic health authorities. At its November meeting, the PRAC requested that makers of GLP-1 medicines provide supplementary information. There’s precedent for weight loss medications being associated with suicidal thoughts and actions. Sanofi-Aventis’s rimonabant, brand name Acomplia, won EMA approval as an obesity drug in 2006. The small molecule drug was designed to target and block cannabinoid receptor type 1. In addition to its a role in mood and anxiety, this receptor also plays a role in appetite. However, the targeting of the receptor for appetite may have also triggered psychiatric effects. Those concerns prompted a regulatory review that concluded Acomplia’s benefits no longer outweigh its risks. Acomplia never reached the U.S. market. Sanofi-Aventis withdrew its FDA application after an advisory committee in 2007 voted against recommending approval.

Drug Approval

09 Jan 2024

·www.biospace.com

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(News - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") to initiate a Phase 2 clinical trial of nimacimab in patients with obesity and chronic kidney disease. Skye plans to initiate the Phase 2 trial in mid-2024. Nimacimab is a negative allosteric-modulating antibody targeting the cannabinoid 1 receptor ("CB1"), which has been implicated as an important target in cardiometabolic diseases including obesity and renal complications. The high correlation of these comorbid conditions, with 80% of patients with kidney disease being obese and 30% of obese patients having kidney disease, represents an opportunity for a mechanism that can affect their common underlying disease processes. Nimacimab was observed to have very limited accumulation in the CNS in pre-clinical studies, a safety issue in earlier generations of CB1 inhibitors. Safety and tolerability assessments from the completed Phase 1b study of nimacimab in non-alcoholic fatty liver disease ("NAFLD") patients with diabetes or prediabetes demonstrated no serious adverse events, no early terminations of treatment due to adverse events, and no adverse events of concern occurring in a dose-dependent manner. Encouraging trends were observed in exploratory biomarkers including cholesterol, liver enzymes and liver function in patients receiving nimacimab versus placebo after the four-week dosing period. Moreover, pharmacokinetic assessment of nimacimab highlighted a half-life of approximately three weeks, potentially allowing for monthly dosing, which would offer a competitive advantage over once-a-week subcutaneous dosing of current peptidic GLP-1 receptor agonists. Additionally, third-party research has strongly indicated the role of CB1 inhibition in modifying insulin and leptin sensitivity, preserving lean mass, and ultimately augmenting durability of weight loss. With nimacimab's differentiated characteristics, this novel molecule may provide an important alternative as a single or combination therapy targeting obesity and other metabolic, inflammatory and fibrotic conditions. "We believe that the encouraging safety pro nimacimab from preclinical and clinical studies exceeds that of small molecule CB1 inhibitors and that this class of drug offers the potential to treat a range of metabolic conditions," said Tu Diep, Chief Development Officer of Skye. "We look forward to evaluating multiple meaningful clinical endpoints in the Phase 2 trial, including weight loss, changes in albuminuria related to kidney function, and other biomarkers, in order to guide the future development of nimacimab." "With the growth of GLP-1 agonists we are also seeing large pharmaceutical companies acquiring drugs with complementary mechanisms of action to treat obesity," said Punit Dhillon, CEO and Chair of Skye. "We see peripheral CB1 inhibition playing a strong role in future combination therapies and are advancing nimacimab as a key possible component of such combinations." About the Endocannabinoid System and Peripheral CB1 Inhibition for Weight Loss The endocannabinoid system ("ECS") has emerged as one of the most relevant regulators of energy balance. The ECS acts through two cannabinoid receptors: types 1 and 2 (CB1 and CB2). CB1 is widely expressed in the CNS and brain but is also expressed in peripheral tissues such as adipose tissue, skeletal muscle, and in the liver, kidney, gut, and pancreas. In obese states, CB1 agonists such as anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), the body's naturally-produced endocannabinoids, are increased and may exert unfavorable effects on insulin-sensitive tissues. Peripheral inhibition of CB1 has been shown to cause a reduction in food intake and sustained weight loss through multiple mechanisms, including increasing incretin expression in the gut and reducing ghrelin expression. The ECS also contributes to the control of lipid and glucose metabolism, and it is well established that blockade of CB1 receptors enhances insulin sensitivity in both humans and rodents. Clinically, early development of small molecule drugs that blocked CB1 appeared encouraging with the approval of rimonabant (Sanofi) in Europe for weight loss and obesity. However, it was soon removed from the market because of side effects related to the high exposure of the drug to the CNS and brain, which resulted in safety issues such as depression, anxiety and suicidal ideation. A new class of drugs are now designed to only target CB1 in the periphery, while avoiding the CNS. About Nimacimab Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of diseases with notable unmet medical needs such as obesity, chronic kidney disease, and non-alcoholic steatohepatitis (NASH). Preclinical studies over 26 weeks showed that nimacimab has very limited accumulation in the brain. The safety and tolerability assessments from the completed Phase 1b study of nimacimab in non-alcoholic fatty liver disease ("NAFLD") patients with diabetes or prediabetes demonstrated no serious adverse events, no early terminations of treatment due to adverse events, and no adverse events of concern occurring in a dose-dependent manner. The most frequently reported treatment-emergent adverse events (>5% of subjects) in the pooled nimacimab and placebo groups were diarrhea, headache, dizziness (9.5 vs. 5.0%), upper respiratory tract infection, nausea and vomiting. Encouraging trends were observed in exploratory biomarkers of cholesterol, liver enzymes and liver function in patients receiving nimacimab versus placebo after the three-week dosing period. The promising PK data of approximately 21 days from the Phase 1 study suggests that nimacimab can be dosed once-a-month subcutaneously, which would potentially offer a competitive advantage over once-a-week subcutaneous dosing of current peptidic GLP-1 receptor agonists or even orally dosed GLP-1 receptor agonists due to their less desirable tolerability profile. About Skye Bioscience Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes. Backed by leading life science venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, showed a favorable safety and tolerability pro a Phase 1 study. Skye plans to start a Phase 2 study in obesity and chronic kidney disease for nimacimab in mid-2024. SBI-100 Ophthalmic Emulsion, a CB1 agonist, is currently being studied in a Phase 2 study of patients with glaucoma and ocular hypertension. For more information, please visit: . CONTACT Investor Relations ir@skyebioscience.com (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@lifesciadvisors.com 617-308-4306 FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements. To view the source version of this press release, please visit

Phase 1Phase 2Clinical ResultIND

100 Deals associated with Rimonabant

External Link

KEGG	Wiki	ATC	Drug Bank
D05731	Rimonabant	A08AX01	DB06155

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	EU	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	IS	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	LI	Sanofi-Aventis Ltd.	19 Jun 2006
Obesity	NO	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	EU	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	IS	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	LI	Sanofi-Aventis Ltd.	19 Jun 2006
Overweight	NO	Sanofi-Aventis Ltd.	19 Jun 2006

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus	Phase 3	US	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	CN	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	AR	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	AU	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	BE	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	BR	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	CL	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	CO	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	HR	Sanofi	01 Jan 2008
Diabetes Mellitus	Phase 3	FR	Sanofi	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00656487 (CTgov)	Phase 2	Marijuana Abuse \| Cannabis withdrawal	66	Rimonabant (Rimonabant)	pcutbpxaes(brdixmhmhn) = jznzutkkwh rfynqcymys (nowqgoqite, leowxxnkru - okbczrkfjz) View more	-	15 May 2017
				placebo (Placebo)	pcutbpxaes(brdixmhmhn) = ovpctoknxl rfynqcymys (nowqgoqite, rrusqrzrvo - miuqgtouvn) View more
NCT00547118 (CTgov)	Phase 2	Schizoaffective disorder \| Smoking \| Obesity ... View more	17	Rimonabant (Rimonabant)	rlwbjrxxhx(hqvtcjtvld) = hggvrezvjb gbbkdinzky (mdzlwcirbu, qlmlmitgbb - vcmgiqbsjj) View more	-	27 Feb 2015
				Placebo (Placebo)	rlwbjrxxhx(hqvtcjtvld) = vpbnayhblv gbbkdinzky (mdzlwcirbu, twrclwlble - zfsmpvmsic) View more
NCT00263042 (Pubmed \| Lancet)	Phase 3	-	18,695	Rimonabant 20 mg	acrrnskltu(qvtyreatpc) = 3038 [33%] vs 2084 [22%] dhommdiyhx (gbdbbffawm ) View more	-	14 Aug 2010
				Placebo
NCT00458718 (Pubmed \| Addiction)	Phase 3	Smoking Cessation	755	Rimonabant + Nicotine patch	khehfnlyzz(grayfwihwd) = qhpkfgihmk irhnyzspum (vbgrcsicgu )	Positive	01 Feb 2009
				Rimonabant only	khehfnlyzz(grayfwihwd) = pdtheatziq irhnyzspum (vbgrcsicgu )
NCT00124332 (Pubmed \| JAMA)	Phase 3	Coronary Artery Disease \| Obesity, Abdominal	839	Rimonabant	abkvwyzgfj(lleolvftvn) = osykocfyut osbgiyrrnj (myfzvekicb, -0.04% - 0.54%) View more	-	02 Apr 2008
				Placebo	abkvwyzgfj(lleolvftvn) = mhnfwwgkul osbgiyrrnj (myfzvekicb, 0.22% - 0.80%) View more
NCT00029835 (RIO-Lipids, Pubmed \| Br Dent J)	Phase 3	Dyslipidemias \| Overweight	1,036	Placebo	bsmjlrrgan(laleeqkvuf) = foodyfaxaj hfjepuhjkf (dufyhbkusl ) View more	-	17 Nov 2005
				Rimonabant 5 mg	bsmjlrrgan(laleeqkvuf) = fmnryvwybl hfjepuhjkf (dufyhbkusl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis